Newsfile Corp
15 Jun 2026, 20:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Lisata Therapeutics (LSTA) is being acquired by Kuva Labs for $4.00 per share in cash plus two contingent value rights (CVRs) of $1.00 each. — The announcement of a definitive acquisition price typically creates a price floor and a catalyst for immediate valuation adjustment.
+0.60The law firm Brodsky & Smith is investigating the Lisata Board for potential breaches of fiduciary duty regarding whether the sale price provides fair value to shareholders. — Legal challenges to a merger can create uncertainty, delay closing, or lead to demands for a higher purchase price, introducing volatility.
-0.30Which stocks this story touches
The company is under investigation by a law firm for potential breaches of fiduciary duty regarding its sale to Kuva Labs.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is the subject of a shareholder notice announcing a legal investigation.
The company is the subject of a shareholder notice announcing a legal investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
2h ago
